NCT05670821Completed
PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms
Post-marketing Surveillance of Spesolimab I.V. Infusion in Improvement of Generalized Pustular Psoriasis (GPP) With Acute Symptoms in Japan
Source: ClinicalTrials.gov · Last updated 20 Oct 2025
Brief summary (registry, in English)
Non-interventional cohort study in patients with newly initiated Spesolimab to evaluate the incidence of adverse drug reactions and to understand generalized pustular psoriasis (GPP) disease activities in the real world setting.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 52 (actual)
- First submitted
- 2 Jan 2023
- Start date
- 18 Apr 2023
- Primary completion date
- 6 Oct 2025
- Lead sponsor
- Boehringer Ingelheim
- Diseases
- Psoriasis
- NCT number
- NCT05670821
What you commit to
- Study type: Observational
- Participants enrolled: 52
- From 18 Apr 2023 to the primary completion date, 6 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- GPP patients with acute symptoms who are administered Spesolimab Intravenous (I.V.) Infusion in Japan
- Patients who have never been treated with Spesolimab I.V. Infusion before enrolment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nippon Boehringer Ingelheim Co., Ltd. Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.